Загрузка...
CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated...
Сохранить в:
| Опубликовано в: : | J Hematol Oncol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6704571/ https://ncbi.nlm.nih.gov/pubmed/31439003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0771-0 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|